Podcast appearances and mentions of princess margaret

This is a personal post and my first post with a request. My wife, life partner and business partner, Ann Hetram, passed away unexpectedly from cancer 2 months ago.  She received excellent care at Princess Margaret Hospital, which is the best cancer hospital in Canada. In her honour, I am co-captain of a team in the Journey to Conquer Cancer walk to support research at Princess Margaret Hospital.  My team is the Harbour Square Team for my condo building. The walk is on Sunday, June 15 at 9 AM. It starts at the University of Toronto, Varsity Stadium, 299 Bloor Street West, Toronto. Donations support breakthrough research, supporting over 1,600 researchers and scientists working on innovative projects, such as early detection methods, personalized cancer treatments, and immunotherapy advancements. Ann's cancer was classified as an “unknown tumor”. She received a personalized cancer treatment including immunotherapy. I'm hopeful that with your support, research will advance to help others facing rare cancers like hers. Whether you walk with us, join virtually, or donate — every step and every dollar counts. Thank you, Ed  

A chaotic, shambolic and critically panned parody, the first on-screen incarnation of Ian Fleming's novel ‘Casino Royale' received its London premiere on 12th April, 1967 - with final edits still being made in the projection room. Nonetheless, it went on to take an extraordinary $40 million at the box office.  Hardnut hero James Bond's adventures had become a swinging Sixties sex comedy starring Peter Sellers, thanks to Fleming's disasterous decision to sell the movie rights to actor Gregory Ratoff for a song long before Bond was known all around the world thanks to the highly succesful film versions of his later books ‘Dr No' and ‘From Russia With Love'. In this episode, Arion, Rebecca and Olly reveal how producer Charles K Feldman assembled such an impressive cast list for his 007 ensemble, including Orson Welles, Ronnie Corbett and Ursula Andress; explain how an on-set visit by Princess Margaret prompted an enormous clash of egos; and ponder why ‘the Spice World of the Sixties' became such a box office hit…  Further Reading: • ‘Casino Royale movie review & film summary' (Roger Ebert, 1967): https://www.rogerebert.com/reviews/casino-royale-1967 • ‘The Casino Royale calamity: how Peter Sellers turned Bond into a laughing stock' (Daily Telegraph, 2021): https://www.telegraph.co.uk/films/0/casino-royale-calamity-peter-sellers-turned-bond-laughing-stock/ • ‘Casino Royale: Official Trailer' (MGM, 1967): https://www.youtube.com/watch?v=onhWav2DejM Love the show? Support us!  Join 

In the early days of the P2P industry, most nonprofits concentrated on one tentpole P2P event—typically a walk or cycling program—which allowed them to align staffing, branding, and resources around a single, large-scale initiative, focusing on broad market appeal. However, as the industry has evolved, so too has the need to diversify offerings—both to engage new audiences and to meet the changing expectations of existing supporters. Expanding into new events definitely comes with its own set of challenges—especially without a clear plan—but it also opens the door to exciting opportunities. With strong internal alignment, consistent branding, and a collaborative approach, building out a mix of P2P campaigns can spark innovation, boost engagement, and drive real growth.In this episode, P2PPF's Marcie Maxwell is joined by Steve Merker, VP of Corporate and Community Partnerships at the Princess Margaret Cancer Foundation, Canada's leading cancer fundraising organization, which was recently recognized as the 2025 Peer-to-Peer Professional Forum Organization Of The Year.  They explore how Princess Margaret expanded its peer-to-peer portfolio from two events to eight, the growing pains and opportunities that come with that kind of scale, and how collaboration, brand clarity and a strategic mindset have fueled their success.In this episode, we'll also explore:Smart strategies for expanding your P2P event lineup without cannibalizing your audienceHow to foster internal alignment and reduce “turf wars” as your portfolio growsWays to create synergy across events while keeping each program's identity strongMentioned LinksRide to Conquer CancerWalk to Conquer CancerRoad Hockey to Conquer CancerJourney to Conquer CancerNorthern Pass to Conquer CancerCricket to Conquer CancerStay Connected on LinkedInConnect with SteveConnect with MarcieConnect with the Peer-to-Peer Professional Forum (00:00) - Welcome to The P2P Soap Box (01:38) - Introducing Steve Merker (07:49) - The Spark of Expansion (11:38) - Navigating Challenges of Event Cross-over (16:13) - Branding (20:13) - Managing Complex Teams (22:56) - Advice for Growth (26:58) - Learn More

Pour yourself a gin, pop on your pearls, and dust off your stiff upper lip as hosts Gráinne Maguire and Chantal Feduchin-Pate peer behind the velvet curtains of royal heartbreak in this special episode of The Way They Were. Joining them for a jolly good gossip is comedian, author, and undisputed queen of feminist history books, Eleanor Morton. Together, they'll dissect the delightfully doomed romance between the original royal rebel, Princess Margaret, and the roguishly charming Lord Snowdon. Expect scandalous insights into swinging sixties soirées, a sassy photographer called Cecil and the worst love notes of all time. Buckle up, dear listeners; it's a right royal affair! Learn more about your ad choices. Visit megaphone.fm/adchoices

Prue Leith reveals her kitchen secrets, discloses how she won her Michelin star, describes the twin disasters of pouring tea for the Queen and setting the kitchen on fire while cooking for Princess Margaret, tells the story of what happened when the Beatles ate at her restaurant, announces her favourite chef, spells out why she's not a food snob, discusses finding love again in her seventies, lets us in on the secret to her happy marriage with John (now her co-star on Prue Leith's Cotswold Kitchen), takes us behind the scenes on The Great British Bakeoff, explains her support for assisted dying, and recounts the time she had breakfast with Winston Churchill. 

Book Club #129 - A Voyage Around The Queen - Richard talks to journalist Craig Brown about his fantastic biography of Queen Elizabeth II, A Voyage Around the Queen. They discuss his glorious tangential approach to biography which he's already used to great effect in books on Princess Margaret and the Beatles, how the Queen in an alternate universe might have been a more anonymous figure, how she had been there through almost all of our lives, the occasionally excretory effect she had on people how met her, whether it's possible to grasp her real character, the profundity of people queuing to see her lying in state, the possible truth about Michael Fagan and how Rich might have figured in the book had he been a little braver. Plus how Royal protocol resulted in Cherie Blair getting pregnant, how Craig upset Donald Trump and the wrong uns that drifted through the Queen's life.Buy the book here - https://www.amazon.co.uk/Voyage-Around-Queen-bestselling-biography/dp/0008557497Come to a RHLSTP live! - https://richardherring.com/rhlstp Become a member at https://plus.acast.com/s/rhlstp. Hosted on Acast. See acast.com/privacy for more information.

A bit of a Christmas treat this… Zandra Rhodes is one of the most recognisable and influential figures in fashion, as well as the founder of the Fashion and Textile Museum in London. Describing herself as both ‘chaotic' and ‘fastidious', she possesses a unique sense of colour and pattern. Over the years, she has dressed some of the world's most famous people from Freddie Mercury, Elizabeth Taylor, Debbie Harry and Diana Ross to royals including Princess Anne, Princess Margaret and Princess Diana. She has also appeared on TV shows such as Absolutely Fabulous and Masterchef. Zandra was made a Dame in 2015, while this year, she published an intimate biography, entitled Iconic: My Life in Fashion in 50 Objects, which shines a light on an utterly extraordinary career. In this Yuletide episode, we talk about: Zandra's ‘more is more' home and studio at Christmas; the importance of working with your hands; festive fun with cult actor Divine; her collecting habit; becoming interested in textile design at art college; her love of drawing; nearly meeting Andy Warhol; why pink is a ‘complicated' colour; how print leads the garment in her work; breaking America; Lauren Bacall stepping on a pin in her studio;  working with the royal family and dressing Freddie Mercury; the influence of friendship and travel on her practice; dealing with cancer; and founding London's Fashion and Textile Museum.Support the show

JCO PO authors Dr. Philippe Bedard (Staff Medical Oncologist at Princess Margaret Cancer Centre and Professor of Medicine at University of Toronto) and Dr. Alberto Hernando Calvo (Medical Oncologist at Vall d´Hebron University Hospital) share insights into their JCO PO article, “Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab,” one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Drs. Bedard and Hernando Calvo discuss how combined transcriptome and ctDNA longitudinal analysis associates with pembrolizumab outcomes. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.  Today we are excited to be joined by Dr. Philippe Bedard, Staff Medical Oncologist at the Princess Margaret Cancer Center and Professor of Medicine at the University of Toronto, as well as by Dr. Alberto Hernando-Calvo, Medical Oncologist at the Vall d'Hebron University Hospital, both authors of the JCO Precision Oncology article titled, “Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab.”  Thank you for joining us today. Phil and Alberto. Dr. Alberto Hernando-Calvo: Thank you. Dr. Philippe Bedard: Great to be with you. Thanks for having us.  Dr. Rafeh Naqash: One of the reasons we do this podcast, as some of the listeners who listen to this podcast regularly may know, is to bring in novel approaches and try to understand how the field is moving towards a space where we are understanding biomarkers better. So your manuscript that was published in JCO Precision Oncology fulfills many of those criteria. And interestingly enough, I was at a conference at the Society for Immunotherapy of Cancer last month earlier in November and a lot of excitement at SITC was revolving around novel transcriptomic biomarkers, proteomic biomarkers or imaging based biomarkers. So could you tell us a little bit about why you started looking at biomarkers? This is an extremely competitive field. Why did you think that looking at the transcriptome is somewhat different from or more interesting from tumor mutational burden PDL-1 than other biomarkers that we currently use? And that question is for you Alberto to start off.  Dr. Alberto Hernando-Calvo: So I think gene expression profiles may have a predictive performance as compared to already existing biomarkers and this was one of the points that we describe in our manuscript. The gene expression signature that we developed back in 2019 at Vall d'Hebron Institute of Oncology was initially developed based on over 45 different tumor types and tested in over 1000 patients treated with antiPD-1 and anti PDL-1. And back then and in this manuscript, we proved that for instance the gene expression signature VIGex that we developed has a potential complementary role to other predictive biomarkers. In this case, we observe this predictive power with ctDNA dynamics and we then see a correlation with other existing biomarkers such as tumor mutational burden. So I don't think we need to use one or the other, but rather they may have additive predictive power. So we need to better individualize predictive biomarkers based on tumor types and select the best combination possible to improve the performance.  Dr. Rafeh Naqash: I completely agree that one size does not fit all, especially in the landscape of immunotherapy. From your perspective, when you developed the original signature, how did you choose what genes to look at? I looked at the manuscript, on the methodology side, some of the signatures are pro-inflammatory STING interferon gamma based, so how did you try to identify that these are the 7 to 10 or whatever number of signatures on the transcriptome side? And then why did you try to combine it with ctDNA based changes?  Dr. Alberto Hernando-Calvo: Back in our initial manuscript, published in Med from Cell Press, we developed the VIGex gene expression signature, as I mentioned, with taking into consideration over 1000 tumor samples from FFPE that we can consider real world samples because they are from real patients coming from the clinic notes as part of real investigational protocol doing or performing biopsies on patients. We did observe after doing a VIGex research and doing different tests, we eventually collected these 12 different genes. Because there is a combination of both genes involved in the interferon gamma pathway, we have genes associated with Tregs as well as T cell memory cells. So it's not only looking at genes that are associated with T cell activation or CD8+ T cell infiltration, but also looking at genes that may be overactivated, overexpressed, an immunosuppressive tumor microenvironment. So it was both selecting genes, the minimum number of genes to do it more scalable and having the minimum dataset of genes and including in the signature genes that are already at targets for immune sequent inhibitors or are being tested in immunotherapy combinations.  Dr. Rafeh Naqash: Thank you. And Phil, for the sake of our listeners, could you elaborate upon this aspect of using ctDNA? So this was tumor-informed ctDNA from what I understood in the manuscript. You guys basically try to use it to understand changes in the ctDNA with treatment and then try to combine it with the transcriptome signature. How did the idea come up initially and how did you plan on combining this with an RNA-based signature? Because I have seen manuscripts and other data where people are either using one or the other, but not necessarily both together. So how did you guys come up with that idea? Dr. Philippe Bedard: Well, we thought that this was a great opportunity to look at the combination of the transcriptome as well as the ctDNA dynamics because we had run an investigator-initiated phase 2 clinical trial called INSPIRE at our institution at Princess Margaret from 2016 to 2018, where patients across five different tumor groups received single agent pembrolizumab. And we really did a deep dive on these patients where there were tumor biopsies before and while on treatment. We did exome sequencing, we did RNA sequencing to capture the transcriptome. And in a prior analysis, we had partnered with Natera to look at their Signatera assay, which is a bespoke ctDNA assay, to look at ctDNA dynamics using this test and the association with response outcomes as well as survival outcomes. So we thought that this was a really unique data set to try and address the question of whether or not there was complementarity in terms of looking at the transcriptome and transcriptome signatures of IO benefit together with the ctDNA dynamics. Dr. Rafeh Naqash: From a patient treatment standpoint, it sounded like you mostly tried to include individuals who were treated with pembrolizumab. Did this not include individuals who were treated with chemoimmunotherapy or chemotherapy with pembrolizumab? Just pembrolizumab alone? And if that's the case, some of the tumor types there included, from what I remember, ovarian cancer and some other unusual cancers that don't necessarily have approvals for single agent pembrolizumab, but perhaps in the TMB-high setting. So can you elaborate on the patient selection there for the study?  Dr. Philippe Bedard: Yeah, that's a great question. So at the time that the study was designed in 2015, this was really the early days of immune checkpoint inhibitor therapy, so we didn't have the approvals that we have now in specific tumor types for immunotherapy and chemotherapy combinations. So when the study was designed as an investigator initiated clinical trial, the idea was really to capture patients across different tumor types - so head and neck squamous cell carcinoma, malignant melanoma, ovarian cancer, triple negative breast cancer, and a kind of mixed histology solid tumor cohort, where we knew that there were some patients who were going to be immunotherapy responsive, where there was already approvals or evidence of single agent activity, and others where the responses were more anecdotal, to try and understand in a phase 2 clinical trial with kind of a deep dive, which patients benefited from treatment and which didn't. Dr. Rafeh Naqash: Interesting approach. Going to the results, Alberto, could you help us understand some of the important findings from these data? Because there's different sections of how you tried to look at the response rates, the survival, looking at the immune deconvolution, if you could explain that. Dr. Alberto Hernando-Calvo: So the first thing that we tried was to further confirm the external validation of this immune gene expression signature, VIGex in the INSPIRE asset. So what we observed at VIGex-Hot, the category defined by VIGex-Hot tumor microenvironment, was associated with better progression free survival. After including that in a multivariable analysis adjusted by other biomarkers such as TMB, PDL-1 or tumor type, this was also confirmed for overall survival. So then the next step was to really try to hypothesize if the addition of ctDNA dynamics, taking into consideration the ctDNA quantification at baseline as compared to cycle three, if those dynamics could further improve the predictive performance of VIGex categories taken in the baseline samples. What we did observe was that, for instance, VIGex-Hot tumors in baseline tumor samples that were having a ctDNA decrease, as I mentioned before on cycle three assessment as compared to baseline, were having both better progression free survival and better prognosis overall. Another important finding was the evaluation of response rate across tumor types considering both biomarkers. I would say the most important finding is that when we were considering a cold tumor microenvironment in baseline samples before pembrolizumab initiation plus an increase in ctDNA values, what we observed is that those patients were having a 0% response rate. So this may help as a future strategy either for intensification of immunotherapy regimens in a more individualized way or for an early stop to immunotherapy and try to avoid financial toxicities as well as toxicities for our patients. Dr. Rafeh Naqash: From the data that you showed, it seems that there was a strong correlation, as you sort of mentioned, between individuals that had ctDNA clearance and baseline immune pro-inflammatory signatures. So do you really need the transcriptome signature or could the ctDNA just serve as an easy quick surrogate? Because from a cost standpoint, doing whole transcriptome sequencing or more RNA sequencing or tissue standpoint, where tissue is often limited, can become a big issue. So do you think that validation of this may perhaps more revolve around using ctDNA as an easier metric or surrogate? Or am I overestimating the utility of ctDNA? Dr. Philippe Bedard: I think it's a really good question. In our data set which was relatively small, there were 10 patients who had ctDNA clearance, meaning ctDNA that was positive at baseline was not detected. And so 9 out of those 10 patients, as you alluded to, were VIGex-Hot. So the question is a good one, could you do the same with just ctDNA clearance alone, particularly in identifying these patients who really do well, who have long term disease control on immunotherapy? I think it's a tough question to answer because the field is also changing in terms of sensitivity of detection of ctDNA tests. So we know now that there are newer generations of tests which can detect even at logs down in terms of allele variants in the circulation. So I think we need more data to address the question. I think it is important as to what is the best test, what is the endpoint that we should be using from a drug development point of view in terms of really trying to push and understand which treatment regimens are the most effective and have early readouts in terms of activity. Because we all recognize in the clinic that radiographic response doesn't tell the whole story, especially early radiographic assessments using RECIST or other criteria that we apply in clinical trials. Dr. Rafeh Naqash: From a clinical trial standpoint, we often talk about validation of these studies. You may have heard of other tests where, for example, the NCI iMatch, which is incorporating transcriptome sequencing based approach to stratify patients as an integral biomarker for treatment stratification. Is that something that you guys are thinking of using, this approach where individuals who are signature highly inflamed perhaps get lesser therapies or there's a de-intensification of some sort similar to what people are trying to do with ctDNA-based approaches? Dr. Philippe Bedard: I think that's a great question. I think it makes a lot of sense. And certainly, with the new wave antibody drug conjugates in terms of identifying patients who have expression of targets for antibody drug conjugates, that's very attractive as an approach because we don't necessarily have IHC markers for all of the different targets of antibody drug conjugates. We don't necessarily have IHC markers to completely understand different contributions to the tumor microenvironment and whether or not tumors are inflamed. But it's also a challenging approach too because RNA-seq currently is not a routine clinical test. Sometimes there are issues, particularly in patients who have stored specimens that are formalin-fixed and paraffin-embedded in terms of the quality of the RNA for RNA sequencing. And it's not always feasible to get pre-treatment biopsies and turn them around in an approach. So I think it is an attractive approach for clinical trials, but it's a hypothesis that needs to be tested. It's not something that is ready for clinical prime time today in 2024. Dr. Rafeh Naqash: One of the other interesting observations that I came across in your manuscript was that tumor mutational burden, interestingly, did not correlate with signature high tumors. What is the explanation for that? Because generally you would expect a TMB high to perhaps also have an immune gene high signature. Could it have something to do with the tumor types because there was a heterogeneous mixture of tumor type? Or I'm not sure. What else could you possibly think of that you didn't see those correlations or just sample size limitations? Dr. Alberto Hernando-Calvo: Yes. So our findings are consistent with prior data suggesting for instance T cell inflamed gene expression profile was also not correlated with tumor mutational burden and both biomarkers in a prior publication. So to have additive predictive performance for identifying patients most likely to benefit from anti PD-1 regimen, so we somehow were expecting this observation, the fact that both biomarkers are not very correlated. Dr. Rafeh Naqash: So given the proof of concept findings from your study, Phil, what is the next interesting step that you guys are thinking of to expand this? Would you think that a nivolumab-ipilimumab treated cohort would have similar findings? Or is this a treatment specific single agent immunotherapy specific correlation that you found versus something else that you may find in a nivo-ipi cohort or a doublet immune checkpoint cohort?  Dr. Philippe Bedard: The findings are really hypothesis generating. They require additional validation. And you're quite right, there may be nuances in terms of specific tumor types, combinations with other immunotherapy or combinations with chemotherapy or other agents. So I think it would be great if there are other data sets that are collecting this type of information that have ctDNA dynamics and also have transcriptome and potentially exome or genome analysis to look at these types of questions because the field is moving quickly and we really need more data sets in order to understand some of the nuances and greater numbers to validate the signals that we see. Dr. Rafeh Naqash: And one thing, as you said, the field is definitely moving very quickly. I was meeting with a company an hour back and they have an imaging-based approach using fresh tissue to look at pharmacodynamic biomarkers. And I used to work in the NCI with a group that was very interested and they developed an immuno-oncology pharmacodynamic panel that has been used and published in a few clinical trials where they did phosphorylation status. So the final theme that comes out of most of these research based studies that are being done is that one size does not fit all. But the question that comes to my mind is how many things do you necessarily need to combine to get to a predictive biomarker that is useful, that is patient centric, and that perhaps is able to identify the right therapy for the right patient. What is your take on that, Phil?  Dr. Philippe Bedard: Yeah, that's a great question too. The challenge is it depends on the context in terms of what degree of positive predictive value do you need as well as the negative predictive value to drive clinical decisions. So I think in certain situations where you don't have other approved treatment options and with a therapy that is potentially low toxicity and low financial toxicity, then I think the bar is very high in terms of being able to really confidently identify that patients aren't going to benefit. I think the nuance and the challenge becomes when you move into earlier lines of therapy, or when you talk about combinations of agents, or trying to understand within the context of other available options, particularly with treatments that have significant side effect profiles as well as financial risks, then it becomes a much more nuanced question and you really need comparative studies to understand how it fits versus the existing treatment paradigm. So I'm not really answering your question with a specific number because I think it's hard to give you a number. Some of that we also need input from patients in terms of what kind of level of validation do you need and what kind of level of discrimination do you need in order to drive decisions that are meaningful for them. Dr. Rafeh Naqash: Definitely early days, as you pointed out. More and more work in this field will hopefully lead us in the direction that we all want to go in.  Now, going to a different aspect of this podcast, which is trying to understand the trajectories for both of you, Phil and Alberto. And as you mentioned, this project seemed to have started in 2015. So I'm guessing there's a history there between Princess Margaret and Vall d'Hebron. Could you highlight that a little bit? And then perhaps, Alberto, after that you could tell us a little bit about your career when you worked at Princess Margaret as a fellow and then now back at Vall d'Hebron. Phil, you as well. Dr. Philippe Bedard: So absolutely. We have a long history of collaborating with Vall d'Hebron in Barcelona. It's really a great cancer institution with a lot of like minded individuals. We have a formal partnership and we have a lot of informal links in terms of scientists and clinicians who we work with and who we collaborate with on early phase clinical trials, as well as through different investigator networks and other translational projects. So this was really how this collaboration came about and we were fortunate to have Alberto, who came to work with us for two years and brought this great idea of looking at this signature they had developed at Vall d'Hebron in their phase one group and applying it to a data set that we had through the INSPIRE clinical trial.  Dr. Rafeh Naqash: Sounds like a very successful academia-academic collaboration, which is very nice to see. So, Alberto, could you tell us a little bit about your career trajectory and how you ended up at Princess Margaret and then back at Vall d'Hebron and what you do currently? Dr. Alberto Hernando-Calvo: Yes. So I did my oncology residency at Vall d'Hebron in Barcelona, Spain. Then I decided to further specialize in early drug development as well as head and neck cancer oncology. So I decided to pursue a clinical research fellowship under the supervision of Phil Bedard, among others. And so we decided to further validate the signature that we had developed both in the cancer genomic lab at Vall d'Hebron Institute of Oncology and the phase one unit at Vall d'Hebron, and apply the signature that have been originally tested in patients receiving anti PD-1 or anti PDL-1 combinations in early phase clinical trials. In the phase 2 clinical trial of INSPIRE, where we also had ctDNA dynamics and allowed us to test both biomarkers and see that additive predictive power when we were using both. That was one of my research topics under the mentorship of Dr. Bedard and my fellowship at Princess Margaret. And this was one of the manuscripts describing all the findings of this collaboration between Vall d'Hebron and Princess Margaret Cancer Center. Dr. Rafeh Naqash: And then, Phil, if you could highlight some of the things that you've done over the course of your career and perhaps some advice for early career junior investigators and trainees.  Dr. Philippe Bedard: I finished my oncology, medical oncology training at the University of Toronto in 2008. And then I did a breast cancer fellowship in Brussels at Breast International Group. At the time, I was really intrigued because it was really kind of the early days of microarray and RNA signatures in terms of expressing signatures were being used as part of a clinical trial that BIG was running called the MINDACT Study. And so when I finished my fellowship, I came back to Princess Margaret, started on staff. I've been here now for 15 years. I was fortunate to work with the phase 1 group and kind of my career has sort of morphed in terms of early drug development as well as genomics. I've been involved with the American Association for Cancer Research project GENIE, where I'm the current chair. This is really an international data sharing project with panel based sequencing, which both Princess Margaret and Vall d'Hebron have contributed to. And I've been fortunate to work with a number of really talented early career investigators like Alberto, who spend time with us in our drug development program and launched transitional research projects that leverage some existing data sets at their own institutions and also bring together with different research groups at our institution to lead to publications like this one. Dr. Rafeh Naqash: Thank you so much. This was very exciting. Phil and Albert, thanks for joining us today and thank you for allowing us to discuss your interesting manuscript and hopefully we'll see more of this biomarker work from you guys in the near future, perhaps published in JCO Precision Oncology.   And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.     The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Fi's off so Substitute-Jane-M is here and she comes bearing gifts for Dora! Jane and Jane chat bangers from Joseph, liberated female weeing and pleather shorts. Plus, Lady Anne Glenconner, Princess Margaret's lady-in-waiting, discusses her book 'Picnic Papers'. Our next book club pick has been announced! 'The Trouble with Goats and Sheep' by Joanna Cannon. If you want to contact the show to ask a question and get involved in the conversation then please email us: janeandfi@times.radioFollow us on Instagram! @janeandfiPodcast Producer: Eve SalusburyExecutive Producer: Rosie Cutler Hosted on Acast. See acast.com/privacy for more information.

Celebrated chef, restaurateur and TV star Rick Stein, is more than a master of seafood - he's a well-travelled storyteller with a deep-seated love for food that transcends borders. He has a new heart and a fresh outlook on life.Andy Cato, best known as one half of the pioneering electronic duo Groove Armada, is equal parts DJ, musician and forward-thinker - and now mostly a pioneering sustainable agriculture farmer. Lady Anne Glenconner is an aristocrat, author, former lady-in-waiting to Princess Margaret. She's lived a life that reads like a dramatic novel - from royal escapades and tumultuous relationships to personal tragedies; but always with glamour and grit. All that, plus we have the Inheritance Tracks of the author, broadcaster and lover of the outdoors, Kate Humble. Presenters: Nikki Bedi and Huw Stephens Producer: Ben Mitchell

Author and essayist Craig Brown is perhaps best known for his sketch comedy writing and satirical columns poking fun at the British government. But he's also a biographer, having written about subjects like Princess Margaret and The Beatles. Now, he's turned his attention to Queen Elizabeth II in a new biography, Q: A Voyage Around the Queen. In the book, Brown portrays the monarch as an anchor for the British public who penetrated the emotional psyche of a nation–even appearing in people's dreams. In today's episode, Brown joins NPR's Scott Simon to talk about what Queen Elizabeth II symbolized to people, what she would've done with her life had she not been royalty, and the unchanging nature of her character.To listen to Book of the Day sponsor-free and support NPR's book coverage, sign up for Book of the Day+ at plus.npr.org/bookofthedayLearn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

- Ontario Health Minister Sylvia Jones joins the show to discuss New pre-fall economic statement announcement: expansion of fertility services - Homeowners who regularly rent on Airbnb and other sites must pay 13% tax on property value when they sell, recent tax ruling finds. Bob Aaron, real estate lawyer, breaks it down for us- What's your rule for hosting dinners when people have different dietary requests? 

- Prime Minister Trudeau announces massive cuts to Canada's immigration targets- A deputy police chief was allegedly speeding but wasn't ticketed, Toronto Star reporter Brendan Kennedy expands on the story

In this week's episode of Gent's Talk, presented by BULOVA, host Samir Mourani sits down with paralympian hockey player Tyler McGregor to talk about being diagnosed with bone cancer as a young teenager, losing his leg and learning to cope with his new reality, learning to become a hockey player again and what phantom pain really feels like. Tyler shares insights into his career, his life and his recent work with the Princess Margaret foundation. #gentstalk Connect with us! Subscribe here ► https://www.youtube.com/@GentsTalkPodcast Website: https://gentspost.com/ Instagram: https://www.instagram.com/gentspost/ TikTok: https://www.tiktok.com/@gentstalkpod Facebook: https://www.facebook.com/gentspost/ About Gent's Talk: The Gent's Talk series, powered by Gent's Post and presented by BULOVA Canada is an episodic video podcast conversation with leading gents and rising stars across various industries. Guests include Russell Peters, James Blunt, Robin Sharma, Director X, JP Saxe, Wes Hall, Johnny Orlando, Shan Boodram, Dom Gabriel, and Nick Bateman, just to name a few. The conversations range from career, mental health, family, relationships, business, and everything in between. Gent's Talk is the first-ever video podcast to be made available for streaming on all Air Canada domestic/international flights. We aim to have a raw, unfiltered conversations about our guests' lives, how they achieved success, lessons learned along the way, and the challenges encountered. Credits: Host/Producer: Samir Mourani Creative Director and Executive Producer: Steven Branco Video & Sound Editor: Roman Lapshin A STAMINA Group Production, powered by Gent's Post.

被称为“众病之王“的癌症为何棘手？最可怕的癌症种类是哪些？我们真的有希望治愈癌症吗？在依然谈癌色变的今天，我们有幸邀请到了正在 Princess Margaret 癌症研究中心攻读博士学位的Chufan，来和我们分享她在癌症研究领域的求学之路和心路历程。从病人转变身份变为拿刀的人，从临床医学进入科研中心，在这个充满挑战与机遇的领域里，她和病人一起目睹生命的脆弱与坚强，也在实验室里努力为癌症的治愈添一块砖。从本科到硕士再到博士，从湘雅到复旦再到多伦多，Chufan一边自嘲自己抽筋式的科研，也一边建立起了独立科研者的强大内核。让我们跟随节目一起听听关于癌症研究的问题、挑战、发展方向，以及Chufan为我们送上的防癌小贴士-PhD不可能三角之好心态/好作息/无压力（不是！时间码:01:53 医学生刻板印象+1:兴趣爱好是读paper02:36癌症治疗前沿现状：我们还在谈癌色变的时代吗？06:20来自癌症研究PhD的防癌小技巧：50岁以后不要读博（不是09:10 我们真的有希望解决癌症吗？12:28抱着对肿瘤免疫的兴趣，从肺癌研究到乳腺癌研究14:52 肿瘤内科：在无力感中找到边界感，想要“征服”预后差的癌种20:00 从家庭医学百科到第一志愿第一专业录取24:00导师和导师/lab和lab的差别>>国内和国外的就读/科研差别28:17癌症研究实验究竟在做什么？31:22博士生典型：抽筋式科研34:02 当好医生不需要好奇心，但探究精神是好研究员的必需品38:20实验室里日新月异，但临床转化确实又慢又难39:59困难总会过去，掉入下一个坑就会觉得上一个也还好本期节目提到的专业：CancerResearch（癌症研究）BGM by 姚贝娜 - 也许明天

In 1953, Queen Elizabeth II and Princess Margaret attended a glamorous all-night ball. To celebrate the US and Canadian paperback release of my book "The Palace," I'm taking you into the night when Elizabeth II partied at Hampton Court.

We are still all aboard this journey with Dominick Dunne to the 60th birthday party of 3rd Lord Glenconner, Colin Tennant, with all the family. In this second part, we meet up with Princess Margaret, Raquel Welch, and a few other folks with some strong opinions when the American boat sallies up next to the Wind Star. Once the journey is over, there are a few more threads to pull with the fates and legacies of Lord Colin and Princess Margaret. It really all does come back around. Done and Dunne is taking next Monday off from the main feed, returning September 30. Patreon is the place to go to continue your investigation until then with ad-free and bonus episodes!  All sources can be found at doneanddunne.com. To advertise on Done & Dunne, please reach out to info@amplitudemediapartners.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Arnie Aberman received his honorary doctorate of laws from the University of Toronto in June 2015. He is one of more than 1,500 people who have received honorary degrees from UofT since the school began the tradition in 1850, but Aberman believes he is the first and only person to give it back—as his symbolic form of protest against rising antisemitism on campus and his anger at how his former employer is failing to keep students safe, be they Jews or non-Jews. Aberman actually has three other honorary PhDs from other universities, plus an Order of Canada for his contributions to the medical field. But UofT's award was special, because it came after an illustrious career in which Aberman held just about every top post at the institution's medical school over the past 30 years: chair of medicine, dean of medicine and chief of medicine at hospitals in Toronto, including Mount Sinai, Sunnybrook, Princess Margaret, Toronto General and Toronto Western. But the retired physician, 80, no longer wants anything to do with UofT's degree, after he watched the pro-Palestine encampment remain up for two months on campus—just steps away from the medical building. Aberman has now informed UofT's president of his intention to return the honorary degree in the coming days. Aberman joins this episode of The CJN Daily to explain his decision and what he hopes will happen next. What we talked about Read more on U of T Jewish doctors boycotting their university in protest of the school's handling of rising antisemitism and anti-Israel actions on campus, in The CJN. Learn why an Ontario court ordered the U of T encampment dismantled on July 2, 2024, in on July 2, 2024, in The CJN. Hear why UBC medical professor Dr. Ted Rosenberg quit after 30 years because of his university's handling of antisemitism after Oct. 7, in The CJN. Credits Host and writer: Ellin Bessner (@ebessner) Production team: Zachary Kauffman (producer), Michael Fraiman (executive producer) Music: Dov Beck-Levine Support our show Subscribe to The CJN newsletter Donate to The CJN (+ get a charitable tax receipt) Subscribe to The CJN Daily (Not sure how? Click here)

We are taking a voyage this week with Dominick Dunne, who is attending the 60th birthday party bash of Colin Tennant, 3rd Baron Glenconner at the end of 1986. Colin had a great party the decade before and Princess Margaret is no stranger to the party time hedonistic time happening on the island. Dunne attends this celebration, but this is not Nick's first introduction to Princess Margaret. In the first part of this getaway episode, we explore Dunne's previous relationship with Princess Margaret, fill in a bit of backstory on her land and home in Mustique, and get to the boat, right on time, for Colin's party. It truly is a family affair. All sources can be found at doneanddunne.com. Continue your investigation with ad-free and bonus episodes on Patreon! To advertise on Done & Dunne, please reach out to info@amplitudemediapartners.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Our London Lives by Christine Dwyer Hickey. This is wonderful. In 1979 Milly and Pip are misfits, part of the Irish diaspora in London who after a brief romance go their separate ways - but out of sight they're rarely out of mind over the next 40 years. This is an eloquent and wonderful story of lost opportunity and regret, spanning four decades against the landscape of an ever-present London. A Voyage Around the Queen by Craig Brown. This is a biography of Queen Elizabeth the second, by the author who wrote the wonderful Yes, Ma'am about Princess Margaret and One Two Three Four about The Beatles. Combining biography, essays, cultural history, dream diaries, travelogue and satire, he presents a kaleidoscopic portrait of a woman who was the most public, and the most private. LISTEN ABOVESee omnystudio.com/listener for privacy information.

When Queen Elizabeth II was born in 1926, there were years of her childhood that were, compared to other future monarchs, quite normal. After all, she was never supposed to be the Queen. Her father was a second son; her Uncle David would succeed her grandfather, and certainly other male children would come along. And then, in 1930, Elizabeth's parents waited with anticipation to find out the gender of Elizabeth's impending sibling. A boy would be in the line of succession. But the child who arrived was Princess Margaret, who was never supposed to be the daughter and sister of Queens herself, but for the fateful choice her Uncle David would make when Margaret was just six, when everything changed. This episode follows Margaret through a tumultuous childhood, an early doomed romance, and her long, if ill-fated marriage to Antony Armstrong-Jones, eventually the Earl of Snowden. We visit Mustique, the Caribbean island where Margaret's only personal land holdings resided, and meet some of the guests she entertained there. Plus, an assortment of stories about the social life of a notoriously difficult Princess - and why hanging with Margaret wasn't everything it was cracked up to be. It is all going to come back around on your next Dunne Day with Nick's coverage of this Trashy Royal - this is the foundation! Learn more about your ad choices. Visit megaphone.fm/adchoices

When Queen Elizabeth II was born in 1926, there were years of her childhood that were, compared to other future monarchs, quite normal. After all, she was never supposed to be the Queen. Her father was a second son; her Uncle David would succeed her grandfather, and certainly other male children would come along. And then, in 1930, Elizabeth's parents waited with anticipation to find out the gender of Elizabeth's impending sibling. A boy would be in the line of succession. But the child who arrived was Princess Margaret, who was never supposed to be the daughter and sister of Queens herself, but for the fateful choice her Uncle David would make when Margaret was just six, when everything changed. This episode follows Margaret through a tumultuous childhood, an early doomed romance, and her long, if ill-fated marriage to Antony Armstrong-Jones, eventually the Earl of Snowden. We visit Mustique, the Caribbean island where Margaret's only personal land holdings resided, and meet some of the guests she entertained there. Plus, an assortment of stories about the social life of a notoriously difficult Princess - and why hanging with Margaret wasn't everything it was cracked up to be. Listen ad-free at patreon.com/trashyroyalspodcast. To advertise on this podcast, reach out to info@amplitudemediapartners.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Special guest Sarah Sahim joins us to discuss Richard E. Grant's autobiographical film Wah Wah, about the dissolution of his parents marriage and his father's alcoholism, agains the backdrop of the end of British colonial rule in Swaziland. What does this have to do with King Arthur? Well, as a goodbye gift to the visiting Princess Margaret, the British colonial community puts on a production of Camelot with a black Lancelot. A frustrating and frequently incurious film all around that squanders any opportunity to really grapple with the meaning of the end of an empire. Starring Gabriel Byrne, Nicholas Hoult, Emily Watson, and Miranda Richardson. Written and directed by Richard E. Grant.   To hear the entire episode, join the Mary Versus the Movies patreon for $3/month to hear this and the entire series Hollywood Avalon: https://www.patreon.com/maryvsmovies.  

Glamis Castle is situated beside the village of Glamis in Angus, Scotland. It is the home of the Earl of Strathmore and Kinghorne, and is open to the public.Glamis Castle has been the home of the Lyon family since the 14th century, though the present building dates largely from the 17th century. Glamis Castle was the childhood home of the late Queen Elizabeth, The Queen Mother. Her second daughter, Princess Margaret was born there on 21 August 1930.The castle is protected as a category A listed building, and the grounds are included on the Inventory of Gardens and Designed Landscapes in Scotland, the national listing of significant gardens.It also has more ghouls & mysteries patrolling it's castle walls than a Castlevania game.Support the pod:www.patreon.com/monsterfuzzCheck out our merch:https://monster-fuzz.creator-spring.comEverything else!www.linktr.ee/monsterfuzz

La princesse Margaret n'a jamais été une altesse sans couronne. Elle fut au contraire la reine de pique de l'Angleterre, le double extravagant et désespéré de sa sœur Elizabeth. Un miroir brisé qui brillait de tous ses éclats mais dans lequel la royauté n'osait pas se regarder de peur de s'y reconnaître. L'invité Confidentiel : Jérôme Carron, grand reporter au magazine Point de Vue.

Nick is joined by Racing Post senior writer Lee Mottershead to discuss the latest developments in the Horseracing world. Today they begin by looking ahead to an evening of contrasts, with 1,000 Guineas favourite Bedtime Story appearing at Leopardstown coinciding with the start of the Racing League, one of whose Team Captains Kevin Blake joins the show. Also today, trainer Ollie Sangster anticipates big things from Simmering in Saturday's Princess Margaret, Ed Walker looks ahead to English Oak in next week's Lennox Stakes at Glorious Goodwood, ex-jockey George Chaloner tells us about his exciting new venture running Cliff Stud in Yorkshire, while BEBF Chair Simon Sweeting highlights the raft of upcoming high value maiden races. Nick and Lee also have a go at predicting the identity of the new BHA Chair

Welcome to the Instant Trivia podcast episode 1234, where we ask the best trivia on the Internet. Round 1. Category: Margaret Me 1: She led Britain through the 1980s. Margaret Thatcher. 2: I'll get you to name this "Wizard of Oz" actress, my pretty. Margaret Hamilton. 3: Princess Margaret was born in 1930, 4 years after this sister. Elizabeth II. 4: Margaret Burbidge was the first woman to head up this royal observatory. Greenwich. 5: She coined the term "birth control". Margaret Sanger. Round 2. Category: Science Vocabulary 1: "Specific" this is the ratio of a substance's density to that of a standard substance, often water. gravity. 2: It's the resistance that opposes the motion of one surface across another. friction. 3: From a word meaning "insect", it's the study of bugs. entomology. 4: Acone-shapeddeposit ofcalcium saltsthat builds upfrom a cave floor. stalagmite. 5: This adjective from the Greek for "moving" describes the mechanical energy of an object due to motion. kinetic. Round 3. Category: We'Re A North American Band! 1: In 1973 Mammoth thought it cheaper to hire David Lee Roth as a singer than rent his P.A. system; Mammoth became this in '74. Van Halen. 2: This trio sang, "Today's Tom Sawyer, he gets high on you, and the space he invades, he gets by on you". Rush. 3: B-b-b-baby, name this band that topped the charts in 1974"You ain't seen nothin' yet /B-b-b-baby, you just ain't seen nothin' yet /Here's something, here's...". Bachman-Turner Overdrive. 4: This Canadian band was "watchin' 'X-Files' with no lights on, we're dans la maison, I hope the Smoking Man's in this one". Barenaked Ladies. 5: Gordon Gano sang, "I like American music" as the lead singer of this Milwaukee group. the Violent Femmes. Round 4. Category: Current Governors 1: George Pataki. New York. 2: Christine Todd Whitman. New Jersey. 3: Gray Davis. California. 4: Frank Keating. Oklahoma. 5: Tommy Thompson. Wisconsin. Round 5. Category: Trinidad 1: Trinidad's Pitch Lake is a natural lake of this black substance used to surface roads. Tar/asphalt. 2: In 1889 this Caribbean island was joined politically to Trinidad. Tobago. 3: This form of folk music popularized by Belafonte originated in Trinidad. Calypso. 4: U.S.O.C. president Leroy Walker, not Runner, once coached this Trinidadian Olympic team. track and field. 5: What the Trinidadians call Shango, the Haitians call this. Voodoo. Thanks for listening! Come back tomorrow for more exciting trivia!Special thanks to https://blog.feedspot.com/trivia_podcasts/ AI Voices used

On this episode I speak with Set Decorator Alison Harvey about the epic Netflix series “The Crown” Having been on the project for over 8 years this final season holds a special place in telling the life of Queen Elizabeth. This final season included sets that depicted the death of Diana, Princess of Wales, the Golden Jubilee of Elizabeth II, the deaths of Princess Margaret and Queen Elizabeth The Queen Mother, and the wedding of Prince Charles and Camilla Parker Bowles and more. We talk about the color pallant of the decor changing over the seasons, some of the hardest sets to decorate and giving this amazing series a glorious set to end on.

The human dynamo that is Anne de Courcy returns to the podcast by popular demand after her brilliant interview about Princess Margaret and Tony Snowdon. This week she is speaking about one of her most successful books ‘The Viceroy's Daughters', the saga of Lord Curzon and his three talented, beautiful but often wayward daughters at the pinnacle of British and imperial high society in the first half of the 20th Century.Overlapping love affairs, dalliances with dangerous young men and campaigning alongside the most charismatic politician of the age, Oswald Mosley, the former socialist turned fascist leader of Britain's ‘Black Shirts' in the 1930s - this is a story with everything and an incredible window into a glittering but also menacing world of privilege, power and decadence. If you want to support what we do and help us grow this podcast, please hit the ‘Like' button and we now also have a Thank You option on YouTube for donations starting at 2 UK pounds - find it by clicking on the 'three dots' next to the ‘download' button. You can buy Anne's books and those of the other authors we feature in our own bookshop, along with thousands of others. All profit are shared between podcasters and independent booksellers...https://uk.bookshop.org/p/books/the-viceroy-s-daughters-anne-de-courcy/5024095?aid=12054&ean=9780753812556& Looking for the perfect gift for a special scandalous someone - or someone you'd like to get scandalous with? We're here to help...https://www.etsy.com/uk/shop/ScandalMongers *** If you enjoy our work please consider clicking the YouTube subscribe button, even if you listen to us on an audio app. It will help our brand to grow and our content to reach new ears.THE SCANDAL MONGERS PODCAST is also available to watch on YouTube...https://www.youtube.com/@thescandalmongerspodcast/videosAndrew Lownie...https://twitter.com/andrewlowniePhil Craig...https://twitter.com/philmcraigThe Scandal Mongers...https://twitter.com/MongersPodcastYou can get in touch with the show hosts via...team@podcastworld.org(place 'Scandal Mongers' in the heading please).Production byTheo XKerem IsikProduced byPodcastWorld.org Hosted on Acast. See acast.com/privacy for more information.

Drs. Vamsi Velcheti and Nathan Pennell discuss key lung cancer abstracts from the 2024 ASCO Annual Meeting, including data from LUMINOSITY and ADAURA, novel therapies in KRASG12C-mutant advanced NSCLC, and the need for effective adjuvant therapies for patients with rare mutations. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic medical oncology at Perlmutter Cancer Center at NYU Langone Health. Today, I'm delighted to welcome Dr. Nathan Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research at the Taussig Cancer Center. Dr. Pennell is also the editor-in-chief of the ASCO Educational Book. Dr. Pennell is sharing his valuable insights today on key abstracts in lung cancer that will be presented at the 2024 ASCO Annual Meeting. You'll find our full disclosures in the transcript of the episode.  Nate, it's great to have you here on the podcast. Thank you for being here. Dr. Nathan Pennell: Thanks, Vamsi, for inviting me. I'm always excited for the ASCO Annual Meeting, and we have a tremendous amount of exciting lung cancer abstracts. I know we're not going to discuss all of them on this podcast, but even exciting Plenary presentations coming up.  Dr. Vamsi Velcheti: So, one of the abstracts that caught my attention was Abstract 103, the LUMINOSITY trial, which will be presenting the primary analysis at the meeting. So, there's a lot of buzz and excitement around ADCs. Can you comment on this abstract, Nate, and what are your thoughts on key takeaways from this abstract?  Dr. Nathan Pennell: Absolutely, I agree. This is really an exciting new potential target for lung cancer. So historically, when we think about MET and lung cancer, we think about the MET exon 14 skipping mutations which are present in 3% or 4% of adenocarcinoma patients. And we have approved tyrosine kinase inhibitors, small molecule inhibitors that can be very effective for those. What we're talking about here is actually an antibody drug conjugate or ADC telisotuzumab vedotin, which is targeting the MET protein over expression in non-squamous EGFR wild type advanced non-small cell lung cancer. The LUMINOSITY was a single arm, phase 2 study of teliso, and first of all, I think we have to define the patient population. So, these were MET over expressing non-small cell lung cancer by immunohistochemical staining. So, it included both what they considered MET high expression and MET intermediate expression, both of which had to be 3+ IHC positive on 25% to 50% of cells in the intermediate and 50% or higher in the high expressing group. They were treated with the ADC and had pretty promising results, a response rate of 35% in the MET high group and 23% in the intermediate group. Duration of response at nine months and 7.2 months in those two groups, and the PFS was five and a half and six months. So I would say in a previously treated population, this was relatively promising and potentially defines a completely new and unique subgroup of biomarker defined patients. So, Vamsi, I'm curious, though, if this ends up moving forward to further development, what your thoughts are on adding yet another biomarker in non-small cell lung cancer? Dr. Vamsi Velcheti: Yeah, I think it's certainly exciting. I think for this population, we really don't have a lot of options beyond the second line, and even in the second line, docetaxels are low bar. So,I think having more options for our patients is certainly outcome development. And I think MET IHC is relatively easy to deploy in a clinical setting. I think we already test for MET PD-L1 IHC routinely, and now recently, as you know, HER2 IHC given approval for ADCs, HER2 ADCs there in that space. So, I think from a technical standpoint, I don't see a big barrier in terms of adding an additional IHC marker. And usually, the IHC testing is pretty quick. And I think if you have a therapeutic approval based on IHC positivity, I think certainly from an operational standpoint, it shouldn't be a very complicated issue. Dr. Nathan Pennell: Yeah, I agree. This is cheap. It's something that can be done everywhere in the world. And as you said, in addition to diagnostic IHC, we're already looking at PD-L1, and probably moving towards doing that for HER2. This is really wonderful that we're moving into kind of the era of the ADCs, which is opening up a whole new therapeutic group of options for patients. Dr. Vamsi Velcheti: So, the other abstract that caught my attention was like, the Abstract 8005. This is the molecular residual disease MRD analysis from the ADAURA trial. The ADAURA trial, as you all know, is the trial that led to the FDA approval of adjuvant use of osimertinib in patients with EGFR mutant stage 1B through 3A non-small cell lung cancer. And in this trial, osimertinib demonstrated significant improvements in DFS and OS. And in this particular study, Abstract 8005, the authors looked at the role of MRD in predicting DFS in the study. And after 682 patients who were randomized, 36% of the patients had samples to look at MRD post- surgery. And in the trial the MRD status predicted DFS or event free survival at 36 months with a hazard ratio of 0.23. And the MRD status had a median lead time of 4.7 months across both the arms, both osimertinib and the placebo arm. So, suggesting that MRD could potentially identify high risk subgroups of patients post-surgery to tailor personalized approaches potentially in this population. So, Nate, in your practice, of course, we don't have a clinically validated approach yet to kind of use MRD in this setting, but if we have an option to use an MRD based assay, do you think that would potentially be an opportunity to perhaps escalate or de-escalate adjuvant strategies with TKIs in the adjuvant setting? Do you see value in using MRI assays post- surgery? Dr. Nathan Pennell: Yeah, I think this is a really important study because this is such an important topic around adjuvant targeted treatment. So, of course, ADAURA really changed how we treated people with EGFR mutant lung cancer who underwent surgical resection, because we know that the three years of osimertinib significantly improved disease-free survival and overall survival. But there's still a lot of questions being asked about, is that affordable? Obviously, we're putting a lot of resources into three years of treatment, and not everyone necessarily needs it. There may well be people who are cured with surgery alone and adjuvant chemotherapy. And then what about duration? Is three years enough? Do we need even longer treatment, or do we need shorter treatment? And up to date, we haven't really been able to tell people at risk of recurrence other than the pure odds-based risk based on their stage.   And the assay that was used in the ADAURA study was a personalized tumor informed assay based on the resected tumor. It's unclear to me whether this was just a subgroup of people that had this done or whether they tried to do it in all 600 patients and only, it looks like they were successful in about 32% of people. Maybe about a third were able to successfully have a tumor informed assay. So, the first question is, “Can you use this to help guide who needs treatment or not?” And I think what they showed was only about 4% of people in osimertinib arm in 12% had MRD positive at baseline after surgery. So probably, upfront testing is not really going to be all that helpful at determining who's at high risk and needs to be treated.   Interestingly, of those who were positive, though, most of them, or 80% of them, did go MRD negative on osimertinib. And what I found really interesting is that of those who did have a recurrence, 65% of them did have the MRD test turn positive. And as you mentioned, that was about five months prior to being picked up radiographically, and so you can pick them up sooner. And it also looks like about two thirds of recurrences can be identified with the blood test. So that potentially could identify people who are recurring earlier that might be eligible for a more intensive treatment. The other thing that was really interesting is of those who recurred in the osimertinib arm, 68% of them happened after stopping the osimertinib, suggesting that for the majority of patients, even those not necessarily cured, they seem to have disease control while on the osimertinib, suggesting that maybe a longer duration of treatment for those patients could be helpful. The problem is it still isn't necessarily helpful at identifying who those people are who need the longer duration of treatment. So, definitely an important study. I think it could be useful in practice if this was available clinically, especially at monitoring those after completion of treatment. I think as the sensitivity of these MRD assays gets better, these will become more and more important. Dr. Vamsi Velcheti: I think it's a little bit of a challenge in terms of standardizing these assays, and they're like multiple assays, which are currently commercially available. And I think the field is getting really complicated in terms of how you incorporate different assays and different therapeutics in the adjuvant space, especially if you're kind of looking at de-escalating immunotherapeutic strategies at the adjuvant setting, I think, makes it even more challenging. I think exciting times. We definitely need more thoughtful and better studies to really define the role of MRD in the adjuvant space. So, I guess more to come in this space. Dr. Nathan Pennell: Vamsi, I wanted to ask you about another really interesting Abstract 8011. This is a subgroup of the AEGEAN perioperative study for early-stage resected non-small cell lung cancer. This abstract is specifically looking at baseline N2 lymph node involvement in stage 2A-3B with N2 positive patients in an exploratory subgroup analysis. What are your key takeaways from the study?   Dr. Vamsi Velcheti: I felt this was a very interesting abstract for a couple of reasons. As you know, this is the AEGEAN trial, the phase 3 trial that was reported earlier last year. This is a perioperative study of durvalumab plus new adjuvant chemotherapy versus new adjuvant chemotherapy alone and adjuvant durvalumab plus placebo. The study obviously met its primary endpoint, as we all saw, like the event-free survival. And here in this abstract, the authors present an exploratory subgroup analysis of patients who had N2 lymph node involvement prior to study enrollment. So, in this study, they were focusing on perioperative outcomes. And one of the issues that has come up multiple times, as you know, in a lot of these preoperative studies, is the impact of neoadjuvant chemo immunotherapy on surgery or surgical outcomes. And consistently, across a lot of these trials, including the CheckMate 816, about 20% of patients don't end up making it to surgery. So in that light, I think this study and the findings are very interesting. In this study, they looked at patients who had N2 nodal involvement and of the patients with N2 nodal involvement, the surgical operability or the number of patients who completed surgery was similar in both the groups. So, there was no significant difference between patients who received durva versus chemotherapy and also among patients who had N2 subgroup who had surgery, similar proportions of durvalumab and placebo arms had open versus minimally invasive versus pneumonectomy. So durvalumab didn't have a negative impact on the type of surgery that the patients had at the time of surgery. So overall, the findings were consistent with other trials, perioperative trials that we have seen. So, the surgical outcomes were not negatively impacted by adding immunotherapy in the neoadjuvant perioperative space. So, this is consistent with other trials that we have seen. And also, the other issue, Nate, I'd like to get your opinion on is, across the board, in all the perioperative trials we have seen that about 20% of the patients actually don't end up making it a surgery. And of course, most of these perioperative trials, a lot of these patients are stage 3 patients. And my take on this was that there's probably a little bit of a patient selection issue. We generally tend to err on the side of operability when we have a stage 3 patient discussed in the tumor board, sometimes feel like the patient may downstage and could potentially go to surgery. But even in the real world, in stage 3 operable patients, what proportion of patients do you think don't end up going to surgery? Dr. Nathan Pennell: That is such an important question that I don't think we have the best answer to. You're right. All of these perioperative studies have a relatively high- sort of 20% to 30% of people who enroll on the studies don't necessarily go to surgery. And I don't think that they've done as great a job as they could in all of these trials describing exactly what happens to these patients. So in the real world, obviously not everyone would be fit enough to go to surgery or might progress in the time between when they were diagnosed and the time as planned for surgery. But probably more of them would go to surgery if they weren't getting neoadjuvant treatment, because that would be their initial treatment. The question is, of course, is that the right choice? If someone gets 12 weeks or nine weeks of neoadjuvant treatment and then a restaging scan shows that they've had progression with metastatic disease, are those really the people that would have been optimally treated with surgery upfront, or would they just have had recurrence on their first postoperative scan? So, it's really an important question to answer. I think the bigger one is, is the treatment preventing them through toxicity from going to treatment? And I think the studies have generally felt that few patients are missing out on the option of surgery because of toxicity being caused by the IO. And in the AEGEAN study, for example, in this subgroup, a slightly numerically higher percentage of patients in the durvalumab arm actually underwent surgery compared to those who got neoadjuvant chemo. So, it doesn't seem like we're necessarily harming people with the neoadjuvant treatment. But I know that this is a concern for patients and doctors who are undergoing this approach. Dr. Vamsi Velcheti: Definitely, I think having multiple data sets from perioperative trials, looking at the relative impact of IO on the safety and the nature of the surgery is going to be important, and this is a very important study for that reason. Dr. Nathan Pennell: Can I ask you another thing that I thought really interesting about this particular one is they looked at the difference between those with single station N2 and multi station N2. And I know this is one of those, should we be operating on people who have multi station N2 disease? And the AEGEAN study did include people who had multiple N2 stations where perhaps in the pre-IO era, these would have been treated with definitive chemoradiation and not surgery at all. But the disease-free survival hazard ratio was essentially the same for multi station N2 as it was in the overall population. So, has that changed the way we're approaching these patients in these multidisciplinary discussions? Dr. Vamsi Velcheti: Absolutely, Nate. I think surgical operability is in the eye of the beholder. I think it depends on which surgeon sees the patient or how the discussion goes in the tumor boards, as you know. Certainly, I think with this optionality of having a chemo IO option and potential for downstaging, kind of pushes, at least in our practice, more of these patients who are multistation, who would have otherwise gone down the chemoradiation route are now actually going through neo adjuvant chemo IO and with the hope that they would make it to surgery. So, I think it's an interesting change in paradigm in managing our locally advanced patients. So, I think it's certainly interesting, but I guess to your point, there clearly are some patients who probably should just have chemoradiation upfront, and we may be kind of like delaying that definitive chemoradiation approach for at least a subset of patients. So, at the end of the day, I think it's a lot of clinical decision-making and I think there's going to be a little bit of art to managing these patients and it's going to be really hard to define that population for a clinical trial.  Dr. Nathan Pennell: Yeah, clearly, multidisciplinary discussion, still very important for earliest age non-small cell lung cancer patients. If we move back to metastatic lung cancer, let's talk about Abstract 8510 looking at one of our newer, exciting biomarkers, which are the KRASG12Cmutant non-small cell lung cancer. So this is a study of a second generation KRASG12Cinhibitor, olomorasib, which was combined with pembrolizumab, the anti PD-1 antibody, in patients with advanced KRASG12C mutant non-small cell lung cancer. This is something that has been tried before with first generation G12C inhibitors, with some concerns about how safe it was to do that. So, Vamsi, what did you learn from this abstract? Dr. Vamsi Velcheti: Definitely, I think one of the concerns that we've had in other trials is like the cumulative toxicity of adding checkpoint inhibition to G12C inhibitors, especially the sotorasib CodeBreaK trial, where we see increased rates of grade 3, 4 transaminitis. So, it is encouraging to see that some of the newer agents have less of those issues when it comes to combining the checkpoint inhibition. So especially with KRASG12C, as you know, these are patients who are smokers, and often these are patients who have high PDL-1 could potentially also benefit from immunotherapy. In order for these KRASG12C inhibitors, in order to move these targeted therapy options for these patients to the front line, I do think we need to have substantial comfort in combining the checkpoint inhibitors, which is a standard treatment approach for patients in the frontline setting. I think this is exciting, and I think they're also like, as you know, there are other KRASG12C inhibitors also looking to combine with checkpoint inhibition in the frontline settings. So, we'll have to kind of wait and see how the other agents will perform in the setting. Dr. Nathan Pennell: Yeah, I completely agree. I think this is such an important area to explore specifically because unlike our other targeted oncogenes like EGFR and ALK, we have multiple options for these patients, both immunotherapy and targeted treatments. And if we could think about sequencing them or even combining them and if it could be done safely, I think that would be well worth investigating. There still was significant toxicity in this trial; 30% of people had diarrhea, even at the reduced dose, and there was transaminitis at sort of about 20% or so, although probably at a manageable level. But the response rate was really quite promising. And these are all previously IO and mostly G12C TKI pre-treated patients still had a response rate of 63%. And in those who were naive to IO and TKIs, it was 78% response rate. So, if it could be done safely, I think it's definitely worth pursuing this in further trials. Dr. Vamsi Velcheti: And also, there's some data, preclinical data, like looking at G12C inhibition. And also we have known with MET inhibition for a long time that it could potentially augment immune responses and could be having some synergistic effect with IO. So, we'll have to wait and see, I think. But safety is really the top in mind when it comes to combining these agents with checkpoint inhibitors. So, it's really encouraging to see that some of the newer agents may be more combinable IO. Now moving on to the next abstract, and moving on to, again, the early-stage setting. So, Abstract 8052 from our colleagues in Princess Margaret reported outcomes in early-stage non- small cell lung cancer in patients with rare targetable mutation. This is actually becoming increasingly more relevant because we are seeing at least, like with the ALINA data, with the ALK and EGFR, now with ADAURA, we know that these patients don't benefit with adjuvant immunotherapy, especially some of these rare oncogene living mutations, other than like G12C. So I always struggle with this. When you have early-stage patients, with, let's say, a ROS or a RET, where we just don't have data, and we know that those are poor actors because biologically these are aggressive tumors. So, there's a really odd clinical question to ask in terms of, what is the role of adjuvant immunotherapy? Of course, this trial and this abstract are not really addressing that. But what is your take on this abstract? If you could just summarize the abstract for us. Dr. Nathan Pennell: Sure. Well, I think this is incredibly important, and this is an area near and dear to my own heart. And that is, of course, the whole landscape of how we manage early-stage patients has changed with both ADAURA, because we now have effective treatment in the adjuvant setting for EGFR mutant patients, and now more recently with the ALINA trial for adjuvant alectinib for ALK positive patients now being FDA-approved. So, what that means is we actually have to be testing people at diagnosis even before they would be getting adjuvant treatment, and potentially before even surgery to look for these targets. We need the PD-L1 status, we need EGFR and ALK. And if you're going to be looking at these biomarkers, I think there is a reasonable argument to be made that you should be doing broad testing for all of the targetable oncogenes in these patients. There are some studies suggesting that there's value to this and identifying them for treatment at the time of recurrence. But we also know that these patients are at high risk of recurrence and probably need to be investigated, at least in trials for the adjuvant setting. So, this particular study looked at 201 resected, mostly adenocarcinoma patients, and then they basically sequenced them for all of the targeted oncogenes. And they were quite common, perhaps even more common than you might expect in an advanced population. So, 43% of them had KRASG12C mutations, 13% had EGFR Exon 20 mutation, ERBB2 or HER2 mutations found in 11%, MET mutations in 10%, ALK in 7%, ROS1 in 6%, BRAF in 5%, and RET in 2%. So quite common to find these targetable oncogenes in this particular population, perhaps a somewhat biased population at Princess Margaret Hospital, but very common. And then they looked at the outcomes of these patients without targeted adjuvant treatment. And what they found was there was a very high rate of recurrence. So, relapse-free survival was pretty high in these patients across different stages, and generally their prognosis was worse than the more common KRASG12C patients. Most of these, in particular the HER2 mutant patients, seem to have a significantly worse relapse free survival. Interestingly enough, though, that did not carry over to overall survival. Overall survival was better in those who had targetable oncogenes. And my guess is that that probably had to do with the availability of targeted treatments at the time of recurrence that may have impacted overall survival. But I do think that this particularly highlights the need, the unmet need for effective adjuvant treatment in these patients. And most of them, with the exception of KRAS and perhaps BRAF, perhaps MET unlikely to benefit from adjuvant immunotherapy, as you mentioned. And so, I think we really need to be investing in trials of adjuvant targeted treatments in these populations.  Dr. Vamsi Velcheti: Yeah, this is an area that we really don't have a lot of data. But Nate, a question for you. So tomorrow you have a patient with RET fusion, stage 2, N1 disease. What would you do? Would you offer them an adjuvant RET inhibitor? Dr. Nathan Pennell: I think I would search really hard for a trial to give them access. But if you really want to know what I think, and I'm usually willing to tell people what I think, I think the proof of concept is there. I think we know that in the setting of highly effective and very tolerable adjuvant targeted treatment in the EGFR space with osimertinib, in the ALK space with alectinib, if anything, drugs like selpercatinib and pralsetinib in RET fusion positive lung cancer in the advanced setting are just as well tolerated and easily as effective and long lasting. And so, I think if you did a trial and they are doing trials looking at these drugs in the adjuvant space, almost certainly you're going to see the same really dramatic disease-free survival benefit from these treatments, which, at least in the EGFR space, seems to have translated into an improvement in overall survival. And so if I had a stage II or a resected stage 3, especially a RET fusion positive patient today, I would definitely talk to them about off-label use of a RET inhibitor if I could not find a trial. Now, I understand that there are going to be reimbursement issues and whatnot associated with that, but I think the extrapolation is worth discussing. Dr. Vamsi Velcheti: Yeah, I think it's really challenging because some of these fusions are so rare and it's hard to really do large adjuvant trials for some of these rarer subgroups. Nate, fascinating insights. Our listeners will find links to the abstracts we discussed today in the transcript of the episode. And Nate, I look forward to catching up with you at the Annual Meeting, and again after the meeting for our wrap up podcast to discuss the practice-changing lung cancer abstracts and highlights from the Plenary Session. Thank you so much for joining us and sharing your insights today. Dr. Nathan Pennell: Thanks for inviting me. Vamsi. I look forward to touching base after we get to see all the late-breaking abstracts. Like I said, this is, I think, a year for lung cancer with a lot of exciting data, and I know we'll have a lot to talk about. Dr. Vamsi Velcheti And thank you so much to all our listeners for your time. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate and review and subscribe wherever you get your podcast.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Vamsi Velcheti @VamsiVelcheti   Dr. Nathan Pennell @n8pennell   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures: Dr. Vamsi Velcheti: Honoraria: ITeos Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:   Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron  Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Queen Elizabeth and Princess Margaret take a trip down memory lane to a fateful evening at The Ritz. In the present day Margaret's health is declining, but that won't stop her from living her life her way.   To support the LoG on Patreon visit: https://www.patreon.com/lordsofgrantham To buy LoG Merchandise visit: https://www.teepublic.com/user/lords-of-grantham-podcast

The Cannes Film Festival is in full swing in the South of France, and one of the big stories everyone is following concerns Francis Ford Coppola. Forty-five years after he won the Palme d'Or for Apocalypse Now, he is back with his latest film, Megalopolis. He has spent more than $100 million of his own money on the film and is at the festival looking for a distributor. Our own Sam Wasson will tell us how one of the titans of moviemaking found himself hat in hand. Then Stuart Heritage will join us from the U.K., where he will tell us about what is known to be the worst hotel in Great Britain. And James Eli Shiffer has the incredible story of an American woman from Minnesota who discovered that she is the secret daughter of an Italian banker and senator who cavorted with Jackie Kennedy and Princess Margaret and was the face of the 1970s jet set.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Daily Beast reports Even Meghan's Dog Has Been Roped Into Selling Jam.Per the Beast, Mamma Mia—a Beagle who was rescued from an animal testing facility with eight pups—was adopted by Meghan and her husband Prince Harry in 2022, joining their other rescue dog, Guy.Meghan's friend, the noted Jam Enthusiast Abigail Spencer has been   upstaged by photographs of Mamma Mia, nuzzling Spencer in the latest pictures. The presence of the dog playing with Spencer in what looks like a verdant garden suggests that the picture may have been taken at Meghan's $14 million Montecito home.Abigail Spencer's long-lasting friendship with Meghan started back in 2007. Spencer recently recalled the moment, while guesting on the Kelly Clarkson show, saying, "I was doing a pilot for NBC, and I went to read with the people who were supposed to play my best friend. They were testing other actresses. I walk in, I see this beautiful gorgeous creature at the end of the table and I'm like, 'Who is that?' We had an immediate something, you know? And her name is Meghan Markle.""It was just something between us. Our friendship really developed during that time, and deepened. She's an incredible person." We asked our royal insider if they had received one of the 50 jars of Meghans jam.  Deep Crown told us:"Well, well, well. I must say, I'm flattered that you would think I might be among the chosen few, but alas, my pantry remains sadly bereft of the Duchess's culinary creations.. I imagine the list of recipients for Meghan's jam is a veritable who's who of the glitterati, carefully curated to maximize buzz and star power.But really, is this what we've come to? Speculating about the distribution list for a batch of strawberry preserves? I know the royal news cycle can be a bit slow at times, but surely there must be more pressing matters to discuss than the contents of Meghan's kitchen.We decided to ask Deep Crown about Rebel Wilson's Royal Orgy story from yesterday.  They said, “"You know, there's an old saying in London: 'You hear a lot of things in this city, and some of them are even true.'”This is certainly a juicy bit of gossip, isn't it? A wild party attended by a minor royal, complete with drugs, orgies, and all manner of debauchery. It's the kind of story that would have the tabloids salivating and the social set buzzing for weeks, but here we are talking about jam.But you know, as salacious as these details are, I can't say I'm entirely surprised. The British aristocracy has a long and storied history of secret parties and illicit pleasures, dating back centuries. From the hedonistic excesses of the Hellfire Club in the 18th century to the drug-fueled soirées of the Swinging Sixties, there's always been a undercurrent of wild behavior bubbling just beneath the surface of polite society.Of course, the royals themselves are no strangers to this kind of thing. Princess Margaret and Lord Snowdon were notorious for their wild parties and bohemian lifestyle, and there have been plenty of other royals over the years who have been caught up in scandals involving drugs, sex, and other vices.But the key word here is 'secret.' These kinds of parties and behaviors are rarely talked about openly, and when they do come to light, it's often in the form of rumor and innuendo, rather than hard facts. That's why it's so difficult to pin down the identity of the royal in question in this particular case - the aristocracy closes ranks around its own, and there's a powerful incentive to keep these kinds of stories under wraps.

Susannah Constantine first burst onto our TV screens in the late 90s, alongside her partner-in-style, Trinny Woodall. Together, they revolutionised the way women approach fashion with their ground-breaking show 'What Not to Wear', as the iconic duo Trinny & Susannah. The series not only garnered international acclaim but also became a cultural phenomenon, empowering women to embrace their bodies and dress with confidence, taking them all over the world from The Oprah Winfrey Show to the Oscars red carpet. This, we discuss, was just one chapter in Susannah's fascinating life. In her 20s she was in a long-term relationship with Viscount David Linley, the son of Princess Margaret, and we chat today about her travels with Princess Margaret and how she viewed her very much as a mother figure in her life. Susannah is also a bestselling author, and a very successful podcaster - her podcast, My Wardrobe Malfunction, has had 9 seasons, and the most incredible guest lineup from Elizabeth Hurley to Nile Rodgers.Travel quite clearly means a lot to Susannah and she evokes the destinations in her travel diaries today, from Cornwall to Canada, Pakistan to Antarctica, so vividly, and emotively.Destination Recap:Holly - Four Seasons Ritz Lisbon, PortugalSusannah - AntarcticaGassin, France St Tropez, France Olhão, Portugal MustiqueVancouver Island, British Columbia, CanadaClinton, British Columbia, CanadaPakistanHelford Passage, Cornwall Cairngorms, Scotland Soverato, Calabria, Italy Nairobi, KenyaAntarctica Susannah was on a Viking cruise to Antarctica, and Viking provides destination-focused journeys on rivers, oceans and lakes across all seven continents and destination-focused expeditions in Antarctica, the Arctic and North America's Great Lakes. And you can find Susannah' podcast my wardrobe malfunction wherever you get your podcasts. Thanks so much for listening today. If you'd like to hear more from the podcast don't forget to hit subscribe, or if you use Apple Podcasts to press follow so that a new episode lands in your podcast app each week. If you want to be the first find out who is joining me on next week's episode come and follow me on Instagram I'm @hollyrubenstein, and you'll also find me on Threads and TikTok - I'd love to hear from you.And if you can't want until then remember there's the first ten seasons to catch up on, that's over 110 episodes to keep you busy there. Don't forget that all the destinations mentioned by my guests are included in the episode show notes here on your podcast app, and listed on my website, thetraveldiariespodcast.com Hosted on Acast. See acast.com/privacy for more information.

Plus, Elizabeth Hurley is talking about her son filming her in sex scenes?!  Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus, Elizabeth Hurley is talking about her son filming her in sex scenes?!  Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Robert Hardman and Natasha Livingstone for an analysis of "Gelignite" season 1, episode 6 of The Crown.Thanks to The episode focusses on Princess Margaret's relationship with Peter Townsend, our thanks to Nicole, one of our Canadian listeners who suggested this episode. If you'd like us to analyse a favourite episode, get in touch at FactOrFiction@mailonline.co.uk.Find out in this episode of The Crown: Fact or Fiction:Did a journalist from The People uncover the relationship, and how did the newspaper report the story initially?How did Prime Minister Winston Churchill react to the relationship and how did his wife influence him on this matter?What's the significance of the phone number 4832?What was the fallout for the Queen?...And what is an Equerry?!Plus much more. Tell us which episodes of The Crown are your favourites and we might give them the Fact or Fiction treatment on the next episode of the podcast!Email us at FactOrFiction@mailonline.co.ukor send us a message or voicenote on Whatsapp:07796657512 (start your message with "The Crown" so we know which show you're getting in touch with.)Make sure you're following The Crown: Fact Or Fiction so you don't miss an episode. https://podcasts.apple.com/gb/podcast/the-crown-fact-or-fiction/id1714259572 Hosted on Acast. See acast.com/privacy for more information.

This week writer Anne de Courcy joins Andrew and Phil to discuss her extraordinary biography of Lord Snowdon, Antony Armstrong Jones, who was married to Princess Margaret for 18 tumultuous years.A gifted photographer, designer and charity entrepreneur, Lord Snowdon was also a notorious womaniser before, after and during his marriage. His relationship with Margaret veered between affection and bitter recrimination, even cruelty, whilst he cut a dashing swathe through British high society, charming his way out of numerous perilous social and sexual intrigues.Anne's 'semi authorised' biography of Snowdon exposed many new secrets and received huge acclaim. One reviewer said 'The amorous Snowdon was remarkably helpful for this life; the result is jaw-droppingly revealing.You can buy Anne's books at the Scandal Monger's own bookstore, along with thousands of others. All profits are shared between independent booksellers and podcasters.https://uk.bookshop.org/p/books/snowdon-the-biography-anne-de-courcy/4377193?aid=12054&ean=9781474625142&We also now have our own merchandise in a new online shop. You can currently buy a mug, a T shirt and a Sweater, and more products will be added soon. The perfect gift for that special scandalous someone in your life!https://www.etsy.com/uk/shop/ScandalMongers*** If you enjoy our work please consider clicking the YouTube subscribe button, even if you listen to us on an audio app. It will help our brand to grow and our content to reach new ears and eyes.Andrew Lowniehttps://twitter.com/andrewlowniePhil Craighttps://twitter.com/philmcraigScandal Mongershttps://twitter.com/MongersPodcastThe Scandal Mongers Podcast is also available to listen to watch on youtubeYou can get in touch with the show hosts via...team@podcastworld.org (place 'Scandal Mongers' in the heading please).This show is part of the PodcastWorld.org network. For your own show please get in contact via the email address above.Production byTheo XKerem Isik#royals #scandal #scandalmongers#ScandalMongersPodcast #mongersPodcast#PhilCraig #AndrewLownie#snowden #princessmargaret#AnnedeCourcy Hosted on Acast. See acast.com/privacy for more information.

This week, we take The Kid through conquering the 1970s. From hit films like Love Story, The Godfather and The Great Gatsby to two marriages and divorces from Ali MacGraw and Phyllis George, this decade was filled for Robert Evans with all the ups and downs. Appearances in the episode include, but are in no way limited to, Ryan O'Neal, Robert Redford, Al Pacino and even Princess Margaret. All sources can be found at doneanddunne.com. Continue your investigation with ad-free and bonus episodes on Patreon! To advertise on Done & Dunne, please reach out to sales@advertisecast.com or visit https://www.advertisecast.com/DoneDunne. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Spoiler Alert: This bonus episode is all about the last six episodes of The Crown season 6! Ladies Rachel and Roberta are joined by the delightful Sam Sanders, host of Stitcher's Vibe Check podcast, to discuss The Crown's grand finale, from the Princess Margaret bathtub scene to whether Kate ever met Diana in real life. Also, listen in to find out who is crowned the best actor of part 2, what Peter Morgan got right and wrong, and our thoughts on Carole Middleton. That and so much more, so grab a drink and get ready to laugh along with us.--Presented by PureWow and Gallery Media Group. Follow all the royal news at purewow.com/royals. Follow us on Instagram at @RoyallyObsessedPodcast.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Crown: Fact or Fiction, Natasha Livingstone and Robert Hardman take a look at Ritz - Episode 8 of Season 6 of The Crown.This episode of the Crown splits its attention between the end of Princess Margaret's life and the story of the Queen and Princess Margaret's celebration in London on VE day.We answer the questions:What do we know about the Queen and Princess Margaret's celebration of the end of the second world war?Has the Crown got it right with their characterisation of Princess Margaret?Did The Ritz have a secret club hidden from the sight of its genteel patrons?Did the Duke of Edinburgh miss Princess Margaret's birthday celebrations?What drove Princess Margaret's decision to have a very different kind of funeral to other royals?All this and more, in this episode of The Crown: Fact or Fiction. Make sure you're following The Crown: Fact Or Fiction so you don't miss an episode. We love reading your reviews and comments, leave one and we might read it on the next episode!Send The Crown: Fact Or Fiction your views and opinions on Whatsapp: 07796657512 Include the words “The Crown”, “Fact or Fiction” or “FOF” so we know which show you're giving your opinion on, or even leave us a voice note!https://podcasts.apple.com/gb/podcast/the-crown-fact-or-fiction/id1714259572 Hosted on Acast. See acast.com/privacy for more information.

In the aftermath of Princess Margaret's death, the Queen approaches her Golden Jubilee with more trepidation than ever before. With her mother's health in decline, she finds herself vulnerable to the attacks of Mohamed Al Fayed who pursues a high-profile campaign to prove responsibility for Diana's death lies with the Royal Family. Meanwhile, between his blossoming romance with Kate and the re-opened case surrounding his mother's death, William seeks to lead as normal a life as possible while he still can.   Edith Bowman speaks with director Erik Richter-Strand about showing a more vulnerable side of the Queen, and Head of Research Annie Sulzberger introduces researcher Anna Basista to give insight into the Paget Report. Actor Marcia Warren reflects on playing the Queen Mother and Edith meets The Crown's Prince Harry, Luthor Ford – in his first ever interview.   The Crown: The Official Podcast is produced by Netflix and Sony Music Entertainment, in association with Left Bank Pictures.    Host: Edith Bowman  Guests: Erik Richter-Strand, Marcia Warren, Annie Sulzberger, Anna Basista, Luther Ford.

Whilst holidaying in Mustique, Princess Margaret suffers a stroke and is suddenly forced to reassess her lifestyle. Margaret is keen to recover in anticipation of her seventieth birthday, but the Queen remains concerned that her party-loving sister will not be able to kick the habits of a lifetime in order to heal. As Margaret's health continues to decline, she finds herself slipping back into her memories, back to her secret night out with her sister during the biggest party in history: VE Day 1945. The memories from that evening, and what it taught her about her older sister, comfort her in her final days.   Edith Bowman speaks with co-writer Meriel Sheibani-Clare and director Alex Gabassi about exploring Princess Margaret's final years. Producer Martin Harrison talks recreating 1945 and actor Lesley Manville says goodbye to Princess Margaret.   The Crown: The Official Podcast is produced by Netflix and Sony Music Entertainment, in association with Left Bank Pictures.  Host: Edith Bowman  Guests: Meriel Sheibani-Clare, Alex Gabassi, Martin Harrison, Lesley Manville.

Richard, Chris, and Hillary discuss The Crown's farewell to Princess Margaret in season 6, episode 8, "The Ritz"—and later, the celebrated actor details how she prepared for her showcase episode, as well as her long friendship with fellow Crown star Imelda Staunton. 

Bubba and Matt break down S6E02 “Two Photographs” and S6E03 “Dis-Moi Oui” of the final season of The Crown on Netflix in, as Bubba tries unsuccessfully to temper Matt's poor humor in the light of these episodes. We'll be back to explore S6E04 of the Crown, and the rest of the final season soon!. Even though Matt's humor is rarely welcome, we still welcome YOUR thoughts on the episodes discussed, and ALL episodes of the Crown! Send feedback on those episodes to @Lilibetpod on X, or to @DoublePHQ across all social media (including Facebook - https://facebook.com/DoublePHQ), and you can always send emails to mattsaudioblog@gmail.com. We also have a listener/viewer CONTEST for this season! Matt is a historical and hysterical bad pronouncer! Guess as many of what the correct word SHOULD have been as you can and submit them via the ways given above, and the person with the most guesses can win an Amazon gift card from Matt worth one hundred U.S. dollars. Find the mispronunciations here and submit your entries today: https://youtu.be/7KmPSJj6DGI Contest ends December 31st 2023. Matt produces this podcast and video using some sounds and songs licensed through ArtlistIO (https://artlist.io/) and a list of all licenses held can be found in a publicly shared Google Drive folder for inspection: https://drive.google.com/drive/folders/1to5jB5pXtiovOSAkrsaDRaReQQX9TfON?usp=sharing Time Stamps: 00:00:00 Intro 00:00:39 Welcome! 00:02:20 Rating S6E02 “Two Photographs” 00:06:21 Podcast and Contest Information 00:08:52 S6E02 65 Second Recap (That's NEVER 65 Seconds) 00:10:17 Tiny Wheel of Topics: Marc Bolland 00:15:08 Tiny Wheel of Topics: Mario and Duncan 00:19:30 Tiny Wheel of Topics: Diana and Dodi 00:28:16 S6E02 What's Worse? 00:35:53 Rating S6E03 “Dis-Moi Oui” 00:42:59 S6E03 65 Second Recap (That's NEVER 65 Seconds) 00:44:51 Tiny Wheel of Topics: Monte Carlo 00:49:26 Tiny Wheel of Topics: Paparazzi 00:53:30 Tiny Wheel of Topics: Unfinished Business 00:59:25 Tiny Wheel of Topics: The Princes 01:02:04 S6E03 What's Worse? The Crown Season 6 Episodes 2-3 Cast and Crew Information: Directed by Christian Schowkow (Both Episodes) Writing Credits (Both episodes) Peter Morgan... (written by) Meriel Baistow-Clare...(staff writer) & Daniel Marc Janes...(staff writer) Cast S6E02 Imelda Staunton...Queen Elizabeth II Jonathan Pryce...Prince Philip, Duke of Edinburgh Dominic West...Prince Charles Elizabeth Debicki...Princess Diana Lesley Manville...Princess Margaret Salim Daw...Mohamed Al Fayed Khalid Abdalla...Dodi Fayed Rufus Kampa...Young Prince William Fflyn Edwards...Young Prince Harry Claudia Harrison...Princess Anne Marcia Warren...Queen Elizabeth the Queen Mother Sebastian Blunt...Prince Edward Andrew Havill...Robert Fellowes Jamie Parker...Robin Janvrin Ben Lloyd-Hughes...Mark Bolland Lee Otway...Kez Wingfield Harry Anton...Trevor Rees-Jones Enzo Cilenti... Mario Brenna Forbes Masson...Duncan Muir Adam Best...Journalist Nick Jamie Baughan...Journalist Gordon Michelle Andrade...Bianca, Jonikal Maid Stefanie Mueller...Journalist 3 Maria Pietranera...Journalist 4 Sandra Hale...Rita Rogers Amira Ghazalla...Salma, Mohamed's Secretary Mohammed Kamel...Ali Fayed Semo Salha...Salah Fayed Darren Swift...Ken Rutherford Kirstin Murray...Edith Muir Emma Stansfield...Kensington Palace Maid Eszter Toeroek...Celebrity Couple 1 Leo Napier...Celebrity Couple 2 Lee Otway...Kez Wingfield Harry Anton...Trevor Rees-Jones Kate Cook...Susie Orbach Yoann Blanc...Henri Paul Ben Lambert...Ben Murrell Paul Gorostidi...Philippe Dourneau James Aldred...Ritz Waiter Mairi-Clare MacLean...Balmoral Operator Philippe Spall...Parisian Dog Walker Emma Hindle...Balmoral Maid Fred Ledoux...Thierry Rocher Music by Martin Phipps Cinematography by Adriano Goldman Editing by Celia Haining (S6E02) Simon Brasse (S6E03) Casting By Robert Sterne Production Design by Martin Childs Costume Design by Amy Roberts Sidonie Roberts...associate costume designer #TheCrown #Netflix #Royalty #RoyalFamily #QueenElizabeth #PrincessDiana #PrinceWilliam #PrinceHarry #KateMiddleton #DodiFayed #PrincessMargaret #ImeldaStaunton #ElizabethDebicki #DominicWest #JonathanPryce #LesleyManville #PeterMorgan #Paris

Princess Margaret, Queen Elizabeth II's younger sister, was one of the most famous and glamorous women of the 20th century. But her life was lived in view of, and in response to, the tabloid scandals that threatened to undo her. Support Noble Blood: — Bonus episodes, stickers, and scripts on Patreon — Merch! — Order Dana's book, 'Anatomy: A Love Story' and its sequel 'Immortality: A Love Story'See omnystudio.com/listener for privacy information.

Today's guest believes “that flowers speak for themselves.” Rob Van Helden discusses what he means by "perfect simplicity”; starting a business out of the back of a car with his sister Patrice; how, through word of mouth, they were able to grow; and much more on this episode of The Wedding Biz! Rob is the owner of Rob Van Helden Floral Design Limited out of London. His previous clientele includes Nelson Mandela, Joe Malone, Elton John, the Beckham's World Cup party, Alfred Dunhill and James Bond film premieres, and Royal weddings and events including Princess Beatrice, Princess Eugenie, and Princess Margaret's 70th birthday. Rob shares how instrumental props are in the design and setting the theme, and he shares his process when he works with clients. He also speaks about taking his clients to the flower market with him so they can see firsthand what he has in mind for the design and experience their responses. Listen as Rob describes the flower arrangements he designed for his own wedding and some of the biggest challenges he has faced at an event. He shares how he is handling the pandemic personally and professionally and how success to him is simply having happy clients.  Andy is so happy to bring you this revisit of this wonderful and engaging conversation with Rob, and he would really appreciate it if you were to share the podcast with a few friends or colleagues who might enjoy it. Be sure to also leave a top review wherever you listen because that really helps him and the show out, and don't forget to subscribe to the podcast so that you never miss a new episode!   Have you heard about Stop and Smell the Roses with Preston Bailey on The Wedding Biz Network? Listen as Preston shares the secrets, tools, and technologies behind his extraordinary ability to create a theatrical environment out of any space. Also, don't forget about Sean Low's podcast The Business of Being Creative, where Sean discusses the power of being niched, pricing strategies, metrics of success, and so much more. You can find both shows on The Wedding Biz Network.   SUPPORTING THE WEDDING BIZ Become a patron and support Andy and the show! If you are so inspired, contribute!   Time Stamps [01:01] - Today's episode is a revisit of Andy's interview with Rob Van Helden! [02:46] - Rob shares growing up in a small village in Holland and his journey to where he is now. [06:09] - Rob speaks about finding out that he had a knack for floral design. [06:50] - Rob discusses starting a business with his sister Patrice in the back of a car. [08:49] - What does Rob mean by “perfect simplicity”? [09:24] - Learn why Rob likes to work with a lot of one type of flower. [10:29] - Rob discusses why he believes props are instrumental in the design and setting of the theme. [13:29] - Rob has natural conversations with his clients, sends them a proposal, and takes them on a trip to the flower market to show them what he has in mind. [16:51] - What are some of the biggest challenges Rob has had during weddings? [17:50] - Rob describes what he designed for his own wedding in 2007. [20:27] - Rob shares some Royal weddings and events for which he has designed flowers. [22:56] - What events has Rob done for Sir Elton John over the years? [23:48] - Rob discusses how he creates the right display for hotels and their venues. [24:39] - What does success mean to Rob? [25:59 - Andy gives us Rob's contact information. LINKS AND RESOURCES Find Rob: Rob Van Helden Floral Design Limited @rvhfloraldesign Instagram | Facebook | X / Twitter RVH Prop Hire @rvhprophire Instagram | Facebook @rvhhome Instagram | HayKo.TV Follow The Wedding Biz on Social: The Wedding Biz The Wedding Biz on Instagram: @theweddingbiz The Wedding Biz on Facebook: @theweddingbiz The Wedding Biz Network The Music Makers   Support The Wedding Biz by clicking here. Title Sponsor: This episode is sponsored by Kushner Entertainment.

This week's episode is different, and special. Gyles is talking to Anne, Lady Glenconner at a live event at The Barnes Book Fest. A socialite, aristocrat and best-selling author, Lady Glenconner was the best friend and Lady in Waiting to Princess Margaret for many years. She has also had a fascinating and dramatic life of her own, as wife to Colin Tennant, Lord Glenconner. Together they developed the Caribbean island of Mustique and turned it into a destination for the rich and famous. This show features fascinating reminiscences from a rich and long life spent among remarkable people - many of them royal. Anne's latest book Whatever Next, is about her turbulent marriage. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week's episode is different, and special. Gyles is talking to Anne, Lady Glenconner at a live event at The Barnes Book Fest. A socialite, aristocrat and best-selling author, Lady Glenconner was the best friend and Lady in Waiting to Princess Margaret for many years. She has also had a fascinating and dramatic life of her own, as wife to Colin Tennant, Lord Glenconner. Together they developed the Caribbean island of Mustique and turned it into a destination for the rich and famous. This show features fascinating reminiscences from a rich and long life spent among remarkable people - many of them royal. Anne's latest book Whatever Next, is about her turbulent marriage. Learn more about your ad choices. Visit podcastchoices.com/adchoices Hosted on Acast. See acast.com/privacy for more information.